While artificial intelligence has become strategically essential in biopharma commercialization, many teams are struggling with stalled adoption due to piecemeal solutions and the challenges of scaling across decentralized teams.
In this Q&A from World Pharma Today, Hemal Somaiya and Derek Choy share actionable strategies on how to overcome these hurdles by unifying brand and field strategy. Following PharmaForceIQ’s recent acquisition of Aktana, they discuss how combining powerful digital and field orchestration engines allows teams to predict, orchestrate, and measure personalized journeys across personal and nonpersonal channels in a way that is unprecedented in pharma.
Read the full conversation to discover:
- The shift to optichannel marketing: Why the traditional “spray-and-pray” omnichannel approach isn’t working. Learn how investing in an optimal media mix based on real-time signals of intent creates relevance rather than noise.
- AI in customer engagement: Key applications of AI beyond generative uses in content generation, and ways to overcome key challenges in scaling across global teams like using multi-agent systems that can act and adapt in real time
- Real-time measurement and ROI: How unifying impact data allows teams to track key performance indicators like script lift in near real-time, ensuring every dollar is deployed where it yields the highest return.
- Empowering field reps: How AI-driven Next-Best-Action platforms coordinate personal and nonpersonal channels to deliver highly personalized content within 24-48 hours of an HCP seeing a patient, empowering reps to focus their time more effectively, which is particularly vital for specialized areas like rare diseases.